Cutaneous toxicity of a new BRAF inhibitor, LGX818 (encorafenib).
Department of Dermatology, Complejo Hospitalario de Navarra, Navarra, Spain.
Leire Loidi
LL
Pascual
Department of Dermatology, Complejo Hospitalario de Navarra, Navarra, Spain.
Raquel Santesteban
RS
Muruzàbal
Department of Dermatology, Complejo Hospitalario de Navarra, Navarra, Spain.
Maria Laura Álvarez
ML
Gigli
Department of Dermatology, Complejo Hospitalario de Navarra, Navarra, Spain.
Juan Ignacio Yanguas
JI
Bayona
D000368:Aged; D002219:Carbamates / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis*; D005260:Female; D006801:Humans; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000009:adverse effects*
D002219:Carbamates; D013449:Sulfonamides; C000601108:encorafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf